How Much Does Evenity (Romosozumab) Cost in Missouri in 2026?

Missouri Retail Pricing for Evenity in 2026

The wholesale acquisition cost (WAC) for romosozumab sits at $1,825 per monthly dose across Missouri retail pharmacies in 2026. A full 12-month treatment course runs $21,900 before insurance or discount programs. This price has remained stable since Amgen and UCB set it at launch.

Romosozumab is supplied as two prefilled syringes (each containing 105 mg/1.17 mL) that are administered together as a single 210 mg subcutaneous dose 1. The injection is typically given in a healthcare provider's office, which means facility administration fees may add $50 to $200 per visit depending on the clinical setting. Missouri patients paying entirely out of pocket should budget approximately $22,500 to $24,300 when accounting for both drug cost and administration.

Price variation between Missouri pharmacies is minimal for brand-name Evenity because no generic or biosimilar exists as of May 2026. Specialty pharmacies and hospital outpatient departments charge within 2-3% of one another. The real cost differences emerge from insurance tier placement and copay assistance programs.

Missouri Medicaid and Evenity Coverage

Missouri Medicaid does not cover Evenity for osteoporosis indications. Coverage is restricted to type 2 diabetes-related conditions under the current formulary. This gap affects approximately 1.1 million Missourians enrolled in MO HealthNet as of early 2026.

Patients on Missouri Medicaid who need romosozumab face limited options. A provider can submit an exception request documenting treatment failure with bisphosphonates and denosumab, but approval rates for off-formulary osteoporosis biologics remain low in Missouri's fee-for-service program. The ARCH trial (N=4,093) demonstrated that romosozumab reduced new vertebral fractures by 73% compared to alendronate at 24 months 2, which strengthens medical necessity arguments, but the formulary restriction persists.

Dual-eligible patients (those with both Medicare and Medicaid) may have better access through Medicare Part B, which covers physician-administered osteoporosis injections under different criteria. Medicare Part B typically covers Evenity when the patient meets fracture-risk thresholds and has documentation of prior therapy failure or intolerance.

Commercial Insurance Coverage in Missouri

Most major commercial insurers operating in Missouri cover Evenity with prior authorization requirements. Blue Cross Blue Shield of Kansas City, UnitedHealthcare, Anthem, and Cigna all list romosozumab on their specialty pharmacy formularies, though tier placement varies.

Prior authorization criteria across Missouri commercial plans generally require: a confirmed diagnosis of osteoporosis (T-score ≤ -2.5 or fragility fracture history), failure of or contraindication to at least one oral bisphosphonate, and prescribing by an endocrinologist or rheumatologist. Some plans add a second step-therapy requirement involving denosumab or teriparatide before approving romosozumab.

According to the 2020 American Association of Clinical Endocrinology guidelines, romosozumab is recommended as first-line therapy for patients at "very high" fracture risk, defined as a recent fracture within 12 months, T-score below -3.0, or a FRAX score exceeding the intervention threshold 3. Citing this guideline in prior authorization appeals can expedite approvals.

Out-of-pocket costs for commercially insured Missourians range from $0 (with copay assistance) to $300-$500 per injection depending on plan design. Specialty tier placement typically assigns 20-30% coinsurance, which at list price would be $365-$548 per month without additional assistance.

The Amgen/UCB Savings Card: How It Works in Missouri

The manufacturer copay assistance program from Amgen and UCB offers eligible patients up to $1,825 per month in copay support, effectively reducing out-of-pocket costs to $0 for many commercially insured patients. The card covers the gap between what insurance pays and the pharmacy's charge.

Eligibility requirements are straightforward. Patients must carry commercial insurance (not Medicare, Medicaid, Tricare, or other government programs), have a valid prescription for Evenity, and be a U.S. resident. Missouri patients meeting these criteria can enroll online or through their prescribing provider's office.

The savings card has an annual maximum benefit that typically covers the full 12-month treatment course. Patients should confirm their specific benefit cap at enrollment, as it resets annually and the program terms can change. For patients whose coinsurance would exceed the card's monthly maximum, patient assistance foundations like the National Osteoporosis Foundation's access programs or the HealthWell Foundation may bridge remaining gaps.

One common mistake: the savings card cannot be combined with government insurance or used at 340B-covered pharmacies. Missouri patients receiving care at federally qualified health centers should verify their pharmacy's 340B status before assuming the card applies.

503A Compounding Pharmacies in Missouri

Compounded romosozumab is legally available through licensed 503A compounding pharmacies in Missouri. These pharmacies operate under individual patient prescriptions and state pharmacy board oversight.

A critical distinction: compounded biologics are not FDA-approved products. They have not undergone the same manufacturing quality controls, bioequivalence testing, or stability studies as Amgen's commercial Evenity product. The FDA issued guidance in 2023 warning that compounded versions of complex biologics like monoclonal antibodies may have different efficacy and safety profiles than their reference products 4.

Missouri's Board of Pharmacy permits 503A compounding of biologics when a prescriber documents a patient-specific medical need, such as a required dosage adjustment not commercially available. The practical reality is that most endocrinologists and rheumatologists in Missouri do not prescribe compounded romosozumab because the commercial product is available in the standard 210 mg dose that nearly all patients require.

Patients exploring this route should ask: Does the 503A pharmacy have verifiable third-party potency testing? What is their documented stability data? Is the prescribing physician comfortable monitoring outcomes with a non-reference product? These questions matter more for a bone-forming biologic than for simpler compounded medications.

Telehealth Prescribing of Romosozumab in Missouri

Missouri permits telehealth prescribing of Evenity. A physician licensed in Missouri can evaluate a patient via video consultation, review bone density results and fracture history, and issue a prescription without an in-person visit.

The practical limitation is administration. Romosozumab requires subcutaneous injection by a healthcare professional in most cases. While technically a patient or caregiver can be trained for home injection (the device is two prefilled syringes, not an autoinjector), most insurance plans and specialty pharmacies route it through provider-administered channels.

A workable Missouri telehealth pathway looks like this: initial consultation and prescription via telehealth, specialty pharmacy ships the drug to a local infusion center or provider office, and the patient receives monthly injections at that site. Follow-up bone density monitoring and treatment decisions can continue via telehealth appointments.

Missouri's telehealth parity law (RSMo §376.1900) requires commercial insurers to reimburse telehealth services at the same rate as in-person visits, which means the consultation portion carries no additional cost barrier for insured patients.

Comparing Romosozumab to Alternatives Available in Missouri

For Missouri patients facing cost barriers to Evenity, understanding alternative osteoporosis treatments and their relative pricing provides context for decision-making.

Oral alendronate (generic Fosamax) costs $4-$15 per month. Zoledronic acid (generic Reclast) runs approximately $300-$800 per annual infusion. Denosumab (Prolia) costs roughly $1,600-$1,800 per semi-annual injection. Teriparatide (generic Forteo) is approximately $1,200-$3,500 per month depending on source.

The ARCH trial directly compared romosozumab to alendronate and found that 12 months of romosozumab followed by alendronate reduced clinical fractures by 27% compared to alendronate alone (HR 0.73, 95% CI 0.61-0.87, P<0.001) over 33 months of follow-up 2. The FRAME trial (N=7,180) showed romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months 5.

Dr. Felicia Cosman, professor of clinical medicine at Columbia University and lead investigator on the FRAME study, stated: "Romosozumab represents a unique mechanism as the only available agent that both builds new bone and reduces bone resorption simultaneously. For patients at imminent fracture risk, this dual action provides a speed of response that other therapies cannot match" 5.

The FDA label carries a boxed warning regarding cardiovascular risk: romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year 1. Missouri prescribers must weigh fracture reduction benefits against this cardiovascular signal, particularly in older patients with atherosclerotic disease.

Step-by-Step: Getting Evenity Covered in Missouri

The coverage pathway differs based on insurance type, so here is a sequential approach for Missouri patients.

For commercial insurance: Request prior authorization through your prescriber. Provide bone density results (DXA scan), fracture history documentation, and records of prior bisphosphonate use. If denied, file a formal appeal citing AACE 2020 guidelines and ARCH trial efficacy data. Simultaneously enroll in the Amgen/UCB copay card to minimize out-of-pocket once approved.

For Medicare Part B: Evenity is covered as a physician-administered drug. Your provider bills under J-code J3111. Expect 20% coinsurance after the Part B deductible ($257 in 2026), which amounts to approximately $365 per injection. Medigap plans or Medicare Advantage supplemental benefits may cover this coinsurance.

For Missouri Medicaid: File an exception request. Document failed trials of alendronate and denosumab, radiographic evidence of fractures, and FRAX score. Include published clinical evidence. Be prepared for denial and consider the Medicare pathway if dual-eligible.

The Endocrine Society's 2020 clinical practice guideline recommends anabolic therapy (romosozumab or teriparatide) as initial treatment for postmenopausal women with very high fracture risk, rather than starting with antiresorptive agents 6. This recommendation strengthens authorization appeals that challenge step-therapy requirements.

Cardiovascular Safety Considerations

The ARCH trial identified a cardiovascular safety signal: adjudicated major adverse cardiac events occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients over the treatment period 2. This difference was not statistically significant but prompted the FDA to add a boxed warning.

Missouri patients and prescribers should note that the FRAME trial, which compared romosozumab to placebo, did not show the same cardiovascular imbalance (0.6% vs 0.6%) 5. The signal may reflect a protective effect of alendronate rather than harm from romosozumab, but this remains debated.

Pre-treatment cardiovascular screening is standard practice. Patients with a history of MI or stroke within 12 months are contraindicated. Those with multiple cardiovascular risk factors should have a risk-benefit discussion documented in the medical record before initiating therapy.

What Happens After the 12-Month Course

Romosozumab is approved for a single 12-month course only. Bone mineral density gains achieved during treatment begin to reverse within 12 months of discontinuation if no follow-on antiresorptive therapy is started 7.

The standard Missouri practice pattern follows AACE recommendations: complete 12 monthly romosozumab injections, then transition immediately to either denosumab (Prolia, every 6 months) or a bisphosphonate (oral alendronate weekly, or IV zoledronic acid annually) to maintain gains. Missouri patients should plan financially for this sequential therapy from the outset. The follow-on antiresorptive is typically less expensive but represents an ongoing commitment.

Repeat courses of romosozumab have not been studied in large trials and are not FDA-approved. Some specialists prescribe a second course years later based on limited open-label data, but this remains off-label.